|
[TECHNOLOGY
OPPORTUNITY 1992-008]
<<
Back to Life Sciences
Multidrug
Resistant Protein (MRP) Technology
1992-008
Description:
Following
their 1992 discovery of the gene encoding for Multidrug
Resistance Proteins (MRP), Queen’s University
researchers Drs. Susan Cole and Roger Deeley were the
first to clone the human Multi-drug Resistance Protein
1 (MRP1).
The Technology:
MRPs are a subfamily of the ATP-binding Cassette (ABC)
superfamily of transport protein. MRPs are separate
and distinct from the well known family of transporter
proteins called p-glycoproteins. The overexpression
of MRPs are, in part, responsible for the drug-resistance
seen in many tumors. Some of the MRPs are found ubiquitously
in normal human tissue and thus may affect drug distribution,
metabolism and efficacy. We currently have four different
antibodies to various MRP1 epitopes and some of these
can inhibit MRP1 activity.
Applications:
Human MRP1 Antibodies: We currently have four monoclonal
antibodies (QCRL-1 to -4) that can be used for western
blots, immunohistochemistry, immunoprecipitation and/or
flow cytometry. These antibodies can be purchased directly
from PARTEQ Innovations or licensed non-exclusively
for in-house research purposes. There is also the opportunity
for licensee to develop a human monoclonal antibody
therapeutic to inhibit MRP1 activity within human tumors
and thus increase the efficacy of the cancer chemotherapeutic.
MRP Drug Disposition Assay Services: We currently have
various MRP cell lines, vectors and membrane vesicles
for license. This material can be used to develop MRP
drug disposition services for in-house pharmaceutical
research and development. Contract Research Organizations
and other service related companies will find our technology
of interest since they can develop commercial fee-based
MRP drug disposition services. Non-exclusive licenses
are available.
Commercial
Status
The technology described above is protected by numerous
U.S. and foreign patents and applications. Further information
is available upon request. PARTEQ is seeking licensees
for both the antibodies and the drug disposition assay
services.
Contact:
Perry M. Kim, Ph.D.
Manager, Commercial Development
tel: (613) 533-2342 fax: (613) 533-6853
pkim@parteqinnovations.com
|
